CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-celllymphoma
CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-celllymphoma
复制标题
新发弥漫性大B细胞淋巴瘤中CD30的表达及其与MYC和BCL2的相关性
DOI：
10.1136/jclinpath-2018-205039
复制
发表时间：
2018
影响因子：
3.4
通讯作者：
Zhi-Hong Zhang
中科院分区：
文献类型：
--
作者：
Qi-Xing Gong;Zhen Wang;Chong Liu;Xiao Li;Ting-Xun Lu;Jin-Hua Liang;Wei Xu;Jian-Yong Li;Zhi-Hong Zhang
目的CD30+弥漫性 大B细胞淋巴瘤(DLBCL)是一种新的免疫表型变异。然而，根据不同的研究，CD30阳性的发生率是不同的，CD30的预后意义也存在争议。方法收集2008年至2015年中国东部地区初发DLBCL患者2 41例，调查CD30+De 新发DLBCL的发生率、临床病理特征及预后。采用免疫组织化学方法检测CD10、CD30、bcl2、bcl6、MUM1/IRF4、MYC和Ki67的表达，并用荧光原位杂交技术检测MYC和bcl2基因的改变。结果以0% 阈值计算，CD30在新发DLBCL中的阳性表达约为10%。它们主要表现为中心母细胞或间变性形态，较少表现为免疫母细胞形态或星空形态，与MYC基因重排互斥，与BCL2蛋白表达负相关。CD30的表达与患者预后良好相关。但多因素分析显示，它不是新发DLBCL的独立预后因素。结论CD30+DLBCL 可能是具有一定临床病理特征的新生DLBCL亚群，但CD30的预后作用有限。
AimCD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant ofde novoDLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 inde novoDLBCLs and try to find the correlated influences.MethodsA total of 241 patients withde novoDLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+de novoDLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.ResultsUsing a >0% threshold, CD30 expression was detected in approximately 10% patient withde novoDLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or ‘starry sky’ pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients’ outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor inde novoDLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.ConclusionCD30+ DLBCL may be a subset ofde novoDLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.